News

Filter

Current filters:

Amgen

1 to 9 of 1291 results

Amgen's Kyprolis doubles progression-free survival in head-to-head against Velcade

Amgen's Kyprolis doubles progression-free survival in head-to-head against Velcade

02-03-2015

USA-based biotech firm Amgen and its subsidiary Onyx Pharmaceuticals have announced the interim results…

AmgenBiotechnologyKyprolisOncologyResearchUSAVelcade

Three new drugs recommended for approval by EMA/CHMP

Three new drugs recommended for approval by EMA/CHMP

27-02-2015

Three new medicines have been recommended for approval at the February 2015 meeting of the European Medicines…

AmgenEuropeJinarcNephrology and HepatologyNovartisOncologyOtsuka PharmaceuticalPharmaceuticalRegulationRistempaVectibixZykadia

Amgen and Onyx’s MAA for Kyprolis is accepted by EMA

Amgen and Onyx’s MAA for Kyprolis is accepted by EMA

27-02-2015

The European Medicines Agency has accepted the Marketing Authorization Application for Kyprolis (carfilzomib)…

AmgenEuropeKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

Amgen reports its biosimilar ABP 501 meets primary endpoint against adalimumab

04-02-2015

USA-based biotech major Amgen has reported positive top-line data from a Phase III study of its biosimilar…

ABP 501adalimumabAmgenAnti-Arthritics/RheumaticsBiosimilarsHumiraResearchUSA

Amgen and Onyx submit Kyprolis sNDA and marketing authorization application in USA and EU

Amgen and Onyx submit Kyprolis sNDA and marketing authorization application in USA and EU

28-01-2015

USA-based Amgen, the world’s leading independent biotech firm, and its subsidiary Onyx Pharmaceuticals…

AmgenKyprolisOncologyOnyx PharmaceuticalsPharmaceuticalRegulationUSA

Amgen’s 4th-qtr 2014 earnings and sales beat expectations

Amgen’s 4th-qtr 2014 earnings and sales beat expectations

28-01-2015

US biotech major Amgen reported financial results after markets closed yesterday, revealing that fourth-quarter…

AmgenBiotechnologyFinancialUSA

Sanofi and Regeneron’s Praluent BLA gains priority review from US FDA

26-01-2015

The US Food and Drug Administration has accepted for priority review the Biologics License Application…

alirocumabAmgenBiotechnologyCardio-vascularevolocumabPraluentRegeneron PharmaceuticalsRegulationSanofiUSA

1 to 9 of 1291 results

COMPANY SPOTLIGHT

Menarini

Back to top